A novel risk prediction model for post-treatment ischemic stroke recurrence using plasma antithrombin III and thromboelastography

Background

The primary aim of this investigation was to build and test a novel risk prediction model incorporating plasma antithrombin III (ATIII) activity and thrombelastography (TEG)-derived parameters. This approach seeks to enhance the ability to stratify the risk of stroke recurrence among ischemic stroke (IS) patients receiving dual antiplatelet therapy (DAPT).